FOR IMMEDIATE RELEASE
May 9, 2018

Contact: Jeffrey Krasner
(617) 840-9806
jeff@emergingbio.net

Platelet BioGenesis Licenses Induced Pluripotent Stem Cell Technology from iPS Academia Japan

Agreement gives groundbreaking human platelet company access to crucial technologies as it advances its program to manufacture human platelets at scale

Cambridge, Mass., May 9 (Business Wire) – Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale.

Sven Karlsson, co-founder and president of Platelet BioGenesis, said, “This license from iPS Academia Japan is a major milestone for Platelet BioGenesis because it gives us access to an important processing step needed to produce platelets using our novel and exclusive method. With this agreement in place, we have now secured control of all the underlying technology needed to produce donor-independent, life-saving platelets for transfusion.”

Platelet BioGenesis joins a select group of global life science leaders that have been licensed technology from iPS Academia Japan. Its current licensees include Pfizer, Roche, Sanofi, Bayer and Boehringer Ingelheim.

iPS cells are derived from somatic cells such as skin or blood cells, and have been reprogrammed back into an embryonic-like pluripotent state. This enables the iPS cells to develop into almost any type of human cells. At Platelet BioGenesis, the iPS cells are differentiated into megakaryocytes, the cells in the bone marrow that produce platelets,
which are crucial for normal blood clotting and the transport of various factors throughout the body.

iPS Academia Japan is the entity established to commercialize the intellectual property of Kyoto University and other prominent universities and research institutions. The iPS cell patent portfolio primarily issues from the work of Professor Shinya Yamanaka at the Center for iPS Cell Research and Application at Kyoto University.

###

**About Platelet BioGenesis**

Platelet BioGenesis is a venture-backed, development stage biotech company creating designer platelets (PLTs+™) as a new class of therapeutics. Platelet BioGenesis has developed and patented a scalable cGMP-compliant process to generate PLTs+™ from clinical grade induced pluripotent stem cells. The company was spun out of Harvard University and has received funding from the Massachusetts Life Sciences Center and the National Institutes of Health. Learn more at [www.plateletbiogenesis.com](http://www.plateletbiogenesis.com) and follow us on Twitter @plateletbiogen.

**About iPS Academia Japan, Inc.**

[iPS Academia Japan, Inc.](http://www.ips-cell.net) (AJ) is an affiliate of Kyoto University, and its main role is to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other institutions in the field of iPS cell technologies so that the research results contribute to health and welfare worldwide. AJ was established in Kyoto in June 2008. AJ's patent portfolio consists of approximately 130 patent families (470 patent application cases) in iPS cell technologies as of September 2017, and approximately 180 license arrangements have been executed with domestic or international entities. For more information, visit [www.ips-cell.net](http://www.ips-cell.net).